© 2019 by Pregnolia | Privacy Policy

news

Pregnolia was part of the 24 hours report by NZZaS - 13 unique stories that represent Switzerland.

Sabrina Badir presented Pregnolia at the Female Innovation Forum 2019 in front of 200 innovators!

Pregnolia was nominated as one of the TOP 100 Swiss Startups.

The discussion about the framework agreement definitely comes at a critical timing in the Medtech industry that is undergoing dramatic regulatory changes. Are you aware of this, Switzerland?

For more information see the interview by Sabrina Badir.

Pregnolia AG has been awarded an CHF 1.4m SME Instrument Phase 2 grant. This EU Horizon 2020 business innovation grant follows the successful Phase 1 feasibility study and will be invested towards improving the manufacturability of the Pregnolia System. It will allow Pregnolia to streamline the production of its product, increase capacity and facilitate logistics – a fundamental step in company growth.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 873553.

For more information read the latest interview by Sabrina Badir.

Sifted listed Pregnolia as one of the Europe's coolest femtech companies 2019.

Pregnolia was featured in an article in the Handelszeitung regarding women's health.

Pregnolia was selected as one of the 50 Swiss high-tech startups to invest in by the business magazine Bilan and its jury of experienced entrepreneurs.

 

Pregnolia has been named the recipient of a SME Instrument Phase 1 grant. This EU Horizon 2020 business innovation grant provides support for close-to-market feasibility assessment activities. Pregnolia will use the funding for further studying the industrialisation and production scalability of the Pregnolia System.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 835715.

Pregnolia was awarded the Innosuisse Certificate. The Certificate is given by the Innosuisse Innovation Council to startups that are ready for sustainable growth. Pregnolia was one of the seven companies to receive Innosuisse Certificate – former CTI Startup Label – in 2018.

Medtech as a research field has become more important at ETH. The biomechanics engineer Sabrina Badir developed a device that might support the risk assessment of a premature birth. 

Dr. Reihl and Dr. Kohler were elected to the Board of Directors. Both have extensive experience in Medtech and Health Management. 

The ETH-Spin-off Pregnolia has developed a small device to enable gynecologists to measure the cervical stiffness quantitatively. 

The biomechanics Sabrina Badir wants to bring a device to the market that improves risk assessment for preterm birth. That this needs more than the courage for risk, will be discussed during the interview «Focus».

11.2016

Sabrina Badir at OSGG.

Read the article to the congress in info@gynäkologie (german)

Presentation of the device and studies. 

Pregnolia participates at the Global Pitch Fest during the Venture Leaders Programm in Boston.

With the aspiration technique, Sabrina wants to improve diagnosis and prevention of preterm birth. 

Pregnolia obtained 100‘000 Swiss Francs from  W.A. de Vigier Foundation. The ceremony took place in Solothurn.

ETH researcher have developed a sensor to measure the risk for premature birth in the future. 

The probe measures the stiffness of the cervix: The researcher from Zurich wants to improve the assessment of preterm birth with this awardwining idea 

ETH biomechanic Sabrina Badir impressed the jury at the international ideas competition Falling Walls Lab. She developed a device that can determine the risk of a premature birth.

Pregnolia (Pregnostics) wins the prize for the best business idea.